(NASDAQ: NUVL) Nuvalent's forecast annual revenue growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 55.22%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 10.26%.
Nuvalent's revenue in 2025 is $0.On average, 6 Wall Street analysts forecast NUVL's revenue for 2026 to be $1,399,983,682, with the lowest NUVL revenue forecast at $305,187,251, and the highest NUVL revenue forecast at $4,350,893,071. On average, 5 Wall Street analysts forecast NUVL's revenue for 2027 to be $10,137,961,443, with the lowest NUVL revenue forecast at $2,836,446,218, and the highest NUVL revenue forecast at $18,150,383,441.
In 2028, NUVL is forecast to generate $26,525,870,556 in revenue, with the lowest revenue forecast at $11,065,730,687 and the highest revenue forecast at $34,361,930,228.